Investment Rating - The investment rating for the company is "Buy" (maintained) [1][4] Core Insights - The company is expected to face performance pressure in 2024, but the volume of staplers is anticipated to increase in 2025 [4] - The company reported a revenue of 5.27 billion yuan in 2024, a year-over-year decrease of 14.76%, and a net profit attributable to the parent company of 0.57 billion yuan, down 59.39% year-over-year [4] - The company has identified four positive factors for its nurturing business: increased domestic revenue share, accumulated demand for equipment replacement during the pandemic, high-end equipment upgrades, and supportive policies [4] - The stapler business is expected to benefit from three positive factors: increased surgical volume post-pandemic, rising number of hospitals with access, and continued high growth overseas [4] Financial Summary - Revenue is projected to recover to 5.82 billion yuan in 2025, with a year-over-year growth of 10.4% [6] - The net profit attributable to the parent company is expected to increase to 0.72 billion yuan in 2025, reflecting a year-over-year growth of 25% [6] - The gross margin is forecasted to be 56.9% in 2025, slightly improving from 56.5% in 2024 [6] - The company’s earnings per share (EPS) is expected to be 0.25 yuan in 2025, with a price-to-earnings (P/E) ratio of 44.3 [6] Market Position and Growth Potential - The company has a strong position in the electric laparoscopic stapler market, which is characterized by low penetration and high growth potential [5] - The company has launched the world's first intelligent fully automatic turning stapler, enhancing its competitive edge in the market [6] - The overseas stapler market has shown successful incubation, with continued high growth expected [6]